FDA committee to discuss Xarelto for ACS

FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on May 23 to discuss an sNDA from Johnson & Johnson (NYSE:JNJ) for Xarelto rivaroxaban to reduce secondary cardiovascular events in pa...